Brought to you by 
Series C brings in CHF25mm for Symetis SA
08 Oct 2010
Executive Summary
Symetis SA (developing transcatheter aortic valve implantation systems) has raised CHF25mm ($25.8mm) through its Series C venture round. Endeavour Vision and NBGI Ventures co-led the financing (each will contribute one board member) and were joined by current shareholders Truffle Capital, Novartis Venture Fund, Wellington Partners, Vinci Capital & Renaissance PME, Banexi Ventures, and BioMedInvest.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in CHF25mm for Symetis SA
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice